Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  fentanyl citrate
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 40 for your search:
Start Over
Quality Study of Anesthetic Technique on Breast Cancer Surgery
Phase: Phase IV
Type: Supportive care
Status: Completed
Age: 18 to 70
Sponsor: Other
Protocol IDs: 20110920A, NCT01499836
The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
Phase: Phase IV
Type: Supportive care, Treatment
Status: Completed
Age: Over 18
Sponsor: Other
Protocol IDs: 4-2007-0344, NCT01547416
A Dose-Finding Study of Fentanyl (JNS020 QD) 1-Day Transdermal Patch in Participants With Cancer Pain
Phase: Phase III, Phase II
Type: Supportive care
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR014899, JNS020QD-JPN-C02, NCT00644787
Phase III Study of Transdermally Delivered Fentanyl vs Placebo for Pain Management in Cancer Patients (Summary Last Modified 12/91)
Phase: Phase III
Type: Supportive care
Status: Closed
Age: 18 and older
Sponsor: NCI
Protocol IDs: NCCTG-889252, MAYO-889252, NCI-P91-0015
Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: C25608/3039/BP/US, NCT00105287
OraVescent Fentanyl (OVF) for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: 099-15, NCT00105937
Efficacy and Safety of Sublingual Fentanyl Tablets in Treatment of Breakthrough Pain in Cancer Patients.
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 17 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EN3267-005, NCT00262678
Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 17 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EN3267-007, NCT00263575
Study of the Safety of BEMA™ Fentanyl Use for Breakthrough Pain in Cancer Subjects on Chronic Opioid Therapy
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: FEN-202, NCT00293020
Study of BEMA™ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: FEN-201, NCT00293033
Efficacy and Safety of Intranasal Fentanyl in the Treatment of Breakthrough Pain (FT-018-IM)
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: FT-018-IM, 2005-002348-24, NCT00362583
Long Term Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CPO45/06/FCNS, NCT00458510
Efficacy & Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CPO43/06/FCNS, NCT00459277
Comparison of Nasal Fentanyl and Oral Transmucosal Fentanyl (Actiq) in Cancer Breakthrough Pain (FT-019-IM)
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: FT-019-IM, 2006-002087-26, NCT00496392
Evaluate the Use of Paravertebral Block in Reconstructive Breast Surgery
Phase: Phase III
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2006-0961, NCI-2012-01557, NCT00542542
An Efficacy and Safety Study of Fentanyl (JNS020QD) in Participants With Cancer Pain
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR014896, JNS020QD-JPN-C01, NCT00641667
A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 20 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2246-0702, NCT00684632
A Phase III Clinical Study of KW-2246
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 20 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2246-0703, NCT00683995
A Comparative Study of KW-2246
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2246-004, NCT01326689
Nasal Fentanyl for Patient Controlled Treatment of Pain in Cancer
Phase: Phase II, Phase I
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: NFCP1-2010, NCT01248611
Breakthrough Dyspnea Fentanyl Study in Cancer Patients
Phase: Phase II, Phase I
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2011-1007, NCT01515566
Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain
Phase: Phase II
Type: Supportive care
Status: Completed
Age: 3 to 15
Sponsor: Pharmaceutical / Industry
Protocol IDs: C8278/2022/BP/US-CA, NCT00236093
Intranasal Fentanyl for the Treatment of Breakthrough Pain in Cancer Patients (FT-017-IM)
Phase: Phase II
Type: Supportive care
Status: Completed
Age: 18 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: FT-017-IM, 2005-002347-82, NCT00345735
Start Over